Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

Manni Wang; Yuzhu Hu; Ting Yu; Xuelei Ma; Xiawei Wei; Yuquan Wei

doi:10.1016/j.canlet.2018.07.014

Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect

Cancer Lett. 2018 Dec 28:439:113-130. doi: 10.1016/j.canlet.2018.07.014. Epub 2018 Sep 12.

Authors

Manni Wang¹, Yuzhu Hu¹, Ting Yu¹, Xuelei Ma¹, Xiawei Wei², Yuquan Wei¹

Affiliations

¹ Lab of Aging Research and Nanotoxicology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, PR China.
² Lab of Aging Research and Nanotoxicology, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, PR China. Electronic address: xiaweiwei@scu.edu.cn.

PMID: 30218688
DOI: 10.1016/j.canlet.2018.07.014

Abstract

The Human Epidermal Growth Factor Receptor family is composed of 4 structurally related receptor tyrosine kinases that are involved in many human cancers. The efficacy and safety of HER inhibitors have been compared in a wide range of clinical trials, suggesting the superior inhibitory ability of multiple- HER-targeting blockade compared with single receptor antagonists. However, many patients are currently resistant to current therapeutic treatment and novel strategies are warranted to conquer the resistance. Thus, we performed a critical review to summarize the molecular involvement of HER family receptors in tumour progression, recent anti-HER drug development based on clinical trials, and the potential resistance mechanisms of anti-HER therapy.

Keywords: Cancer; Pan-HER; Target therapy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents, Immunological / therapeutic use
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / immunology
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / classification
ErbB Receptors / immunology
Humans
Molecular Targeted Therapy / methods*
Neoplasms / drug therapy*
Neoplasms / immunology
Neoplasms / metabolism
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors*
Receptor Protein-Tyrosine Kinases / classification
Receptor Protein-Tyrosine Kinases / immunology
Signal Transduction / drug effects
Signal Transduction / immunology
Trastuzumab / therapeutic use

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
ErbB Receptors
Receptor Protein-Tyrosine Kinases
Trastuzumab